Drug intelligence / Profile preview

ENOB-DC11

Development stage: Preclinical
Lead developer: Enochian Biosciences
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

**ENOB-DC11** is an investigational cell therapy designed as an allogeneic dendritic cell-based therapeutic vaccine for the treatment of multiple solid tumors, including pancreatic cancer, triple-negative breast cancer, glioblastoma, and renal cell carcinoma. Its mechanism relies on genetically modified allogeneic dendritic cells intended to enhance anti-tumor immune responses. Preclinical studies have demonstrated significant reductions in tumor size in animal models and positive proof-of-concept results in humanized mouse models for pancreatic cancer[1][4][5][7]. The drug is being advanced toward clinical trials by Enochian BioSciences.

Brand names: ENOB-DC11ENOB-DC-11ENOB-DC 11
Other names: ENOB-DC11ENOB-DC-11ENOB-DC 11

Beyond the preview

Go deeper on ENOB-DC11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENOB-DC11.

Explore the full profile